Topical Calcineurin Inhibitors and Malignancy Risk
Journal Title: International Journal of Cancer Management - Year 2017, Vol 10, Issue 4
Abstract
Context The approval of topical calcineurin inhibitors (TCIs) has been a significant breakthrough for the treatment of atopic dermatitis due to much lower systemic absorption and not causing skin atrophy even after long-term use that have made them become popular replacements for topical corticosteroids being almost equally effective. In January 2006, the US food and drug administration (FDA), followed later also by the European medicine agency (EMEA), issued the “black box” warning causing controversy regarding a potential increased risk of lymphoma in patients with atopic dermatitis and treated with TCIs. Evidence Acquisition PubMed and MEDLINE<sup>®</sup> databases were systematically searched utilizing a variety of terms relating to the subject matter. Articles written only in English over the past 15 years were analyzed and selected for review. Results So far, no scientific evidence of the association has been found between use of TCIs, and increased incidence of skin cancers and lymphomas in patients with AD. The systematic review and meta-analysis by Legendre et al. found the role of TCIs unlikely to be a significant risk factor of lymphoma in those patients. Conclusions Despite an extensive body of evidence regarding the TCIs safety, the box warning still remains leaving the physicians and patients unduly uncertain and confused about the safety of TCI use.
Authors and Affiliations
Tamara Cuk Radovic, Kresimir Kostovic, Romana Ceovic, Zrinka Bukvic Mokos
Keywords
Related Articles
- EP ID EP237352
- DOI 10.5812/ijcm.6173
- Views 87
- Downloads 0
Epidemiology of Nervous System Tumors According to WHO 2007 Classification: A Report of 1,164 Cases from a Single Hospital
Background: The central nervous system (CNS) belongs to heterogeneous group of glial and non-glial brain tumors. Increase in the frequency of brain and CNS tumors in Iran have been a cause for debate and concern. Object...
Production of Specific Anti-EGFR Single Chain Antibodies: A Promising Strategy in the Immunotherapy of EGFR Expressing Tumor Tissues
Background: EGFR (Epidermal growth factor receptor) is overexpressed in a number of cancers and plays an important role in several phenomena such as aggressiveness of tumor, decreased survival of the patient, and resista...
Promoter Hypermethylation Analysis of the Tumor Suppressor Genes RASSF1A and RASSF2A in Iranian Endometrial Carcinoma Patients
Introduction The endometrial cancer (EC) is the seventh most common malignancies worldwide among females with good prognosis in early stages of the disease. The CpG Island in the...
Antioxidant Supplements and Breast Cancer: A Systematic Review and Meta-Analysis
Context: Breast cancer is the second most common type of cancer worldwide and the most frequent one among women. Some studies suggest a favorable role of antioxidants on breast cancer, but this is still controversial. O...
Positive Peritoneal Cytology as a Predictor of Prognosis in Early Stage of Endometrioid Adenocarcinoma
Background Peritoneal cytology has been reported to be an independent risk factor for poor survival, but it is not included in the current international federation of gynecology a...